Loading...
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committees
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Press Releases

All releases
    • Regulatory
    • Non Regulatory
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
June 28, 2022
Regulatory

SynAct Pharma AB has been approved for listing on Nasdaq Stockholm

June 21, 2022
Non Regulatory

SynAct Pharma submits CTA for Clinical Phase 2b Study in RA

May 30, 2022
Regulatory

SynAct Pharma publishes Q1 2022 interim report

May 20, 2022
Regulatory

Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022

May 18, 2022
Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 12, 2022
Regulatory

Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB

May 4, 2022
Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 29, 2022
Regulatory

SynAct Pharma AB publishes Annual Report 2021

April 25, 2022
Regulatory

SynAct announces outcome of rights issue

April 20, 2022
Regulatory

Notice of annual general meeting in SynAct Pharma AB

April 1, 2022
Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

March 28, 2022
Regulatory

Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB

March 28, 2022
Regulatory

SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million

March 9, 2022
Regulatory

Notice of extraordinary general meeting in SynAct Pharma AB

March 9, 2022
Regulatory

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

February 11, 2022
Regulatory

Annual Results 2021

January 7, 2022
Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe

Type of information
Language
Read more about how we protect your personal data.